Patients affected by tumors with EGFR mutations have experienced a revolution in treatment landscape due to osimertinib, a very effective precision medicine for lung cancer of non-small cell type (NSCLC).the selective inhibitory power of osimertinib the epidermal growth factor receptor (EGFR) tyrosine kinase, thereby decelerating tumor progression and extending lifespan, contributes to its success.

in everyday medical use, locating suitable biomarkers for forecasting responsiveness and resistance to osimertinib remains a critical challenge.This article aims to delve into the function of osimertinib biomarkers in tailoring treatments for individuals with lung cancer.The main requirement for creating osimertinib biomarkers consists of pinpointing EGFR mutation status in patients with non-small cell lung cancer.

This is crucial for determining the eligibility of patients for osimertinib therapy.In order to detect EGFR mutations, covering exons like 18, 19, 20, and others, exact and trustworthy diagnostic methods, such as the next generation sequencing (NGS) technology (NGS), are essential.Non-small cell lung cancer patients may exhibit substantial variation in their reaction to osimertinib treatment.

It is crucial to locate biological markers that may forecast initial response to osimertinib treatment, which allows doctors to improve treatment therefore also decrease the weight of non-effective treatments.